Gadobutrol

This classification denotes a gadolinium-chelate with the molecular formula C18H31N4O9.Gd, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1BJ477IO2L, chemically known as gadolinium, (10-(2,3-dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-n1,n4,n7,n10,o1,o4,o7)- but more generally known as gadobutrol, which bears U.S. National Institutes of Health Compound Identifier 72057. The European Medicines Agency schedules Gadobutrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07861MIG. The term GADOBUTROL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, No, 3 1992, List 32). The World Health Organization schedules gadobutrol in its Anatomical Therapeutic Chemical (ATC) Classification. GADOBUTROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Gadobutrol under HS 28469000. SMILES: [GAH3].OC(C(N1CCN(CCN(CCN(CC1)CC(=O)O)CC(=O)O)CC(=O)O)CO)CO.